$IRON
Disc Medicine, Inc.

2024 Q3 Form 10-Q Financial Statement

#000095017024093357 Filed on August 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2023 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.171M $7.367M $7.149M
YoY Change 79.98% 40.86% 906.9%
% of Gross Profit
Research & Development $24.69M $23.49M $22.57M
YoY Change 71.2% 94.09% 9.43%
% of Gross Profit
Depreciation & Amortization $11.00K $110.0K $20.00K
YoY Change -63.33% 450.0% -77.78%
% of Gross Profit
Operating Expenses $32.86M $30.85M $29.71M
YoY Change 73.31% 78.05% 39.31%
Operating Profit -$32.86M -$30.85M
YoY Change 73.31% 78.05%
Interest Expense $6.362M $4.573M $6.177M
YoY Change 31.45% 224.33% 4018.0%
% of Operating Profit
Other Income/Expense, Net $6.371M $4.560M -$10.00K
YoY Change 31.2% 224.56% -80.0%
Pretax Income -$26.49M -$26.29M -$23.55M
YoY Change 87.81% 65.12% 10.91%
Income Tax $114.0K $60.00K $32.00K
% Of Pretax Income
Net Earnings -$26.60M -$26.35M -$23.58M
YoY Change 88.35% 65.25% 11.06%
Net Earnings / Revenue
Basic Earnings Per Share -$0.89 -$1.03
Diluted Earnings Per Share -$0.89 -$1.03 -$0.96
COMMON SHARES
Basic Shares Outstanding 29.73M 24.72M 24.14M
Diluted Shares Outstanding 29.94M 25.65M

Balance Sheet

Concept 2024 Q3 2024 Q2 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $487.4M $500.9M $360.4M
YoY Change 31.54% 32.67% 85.19%
Cash & Equivalents $192.6M $280.7M $360.4M
Short-Term Investments $294.7M $220.3M $0.00
Other Short-Term Assets $5.789M $7.296M $5.280M
YoY Change 56.46% 77.95% 35.38%
Inventory
Prepaid Expenses $7.296M $5.280M
Receivables
Other Receivables
Total Short-Term Assets $493.2M $508.2M $365.7M
YoY Change 31.77% 33.14% 84.22%
LONG-TERM ASSETS
Property, Plant & Equipment $79.00K $98.00K $170.0K
YoY Change -56.83% -38.36% 1.19%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $236.0K $236.0K $234.0K
YoY Change 103.45% 103.45% 101.72%
Total Long-Term Assets $1.993M $1.976M $2.334M
YoY Change -10.79% -19.05% 36.17%
TOTAL ASSETS
Total Short-Term Assets $493.2M $508.2M $365.7M
Total Long-Term Assets $1.993M $1.976M $2.334M
Total Assets $495.1M $510.2M $368.0M
YoY Change 31.51% 32.81% 83.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.553M $4.749M $12.63M
YoY Change -58.18% -8.92% -21.86%
Accrued Expenses $5.512M $4.451M $8.145M
YoY Change -0.99% 7.3% 33.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $25.47M $20.31M $21.44M
YoY Change 76.7% 109.75% -5.04%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.712M $1.078M $1.436M
YoY Change -44.77% -67.33% 43.6%
Total Long-Term Liabilities $1.712M $1.078M $1.436M
YoY Change -44.77% -67.33% 43.6%
TOTAL LIABILITIES
Total Short-Term Liabilities $25.47M $20.31M $21.44M
Total Long-Term Liabilities $1.712M $1.078M $1.436M
Total Liabilities $27.19M $21.39M $22.88M
YoY Change 55.14% 65.09% -3.09%
SHAREHOLDERS EQUITY
Retained Earnings -$268.5M -$241.9M -$188.6M
YoY Change 62.63% 60.3% 68.09%
Common Stock $3.000K $3.000K $2.000K
YoY Change 50.0% 50.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $468.0M $488.8M $345.1M
YoY Change
Total Liabilities & Shareholders Equity $495.1M $510.2M $368.0M
YoY Change 31.51% 32.81% 83.81%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2023 Q4
OPERATING ACTIVITIES
Net Income -$26.60M -$26.35M -$23.58M
YoY Change 88.35% 65.25% 11.06%
Depreciation, Depletion And Amortization $11.00K $110.0K $20.00K
YoY Change -63.33% 450.0% -77.78%
Cash From Operating Activities -$17.36M -$15.39M -$17.79M
YoY Change 132.1% 21.01% 43.48%
INVESTING ACTIVITIES
Capital Expenditures -$8.000K -$3.000K -$1.000K
YoY Change -116.0% -130.0% -100.67%
Acquisitions
YoY Change
Other Investing Activities -$71.10M -$219.8M
YoY Change
Cash From Investing Activities -$71.09M -$219.7M $1.000K
YoY Change 142080.0% 2197390.0% -100.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 426.0K 173.2M 7.759M
YoY Change -7.39% 12.57% -94.97%
NET CHANGE
Cash From Operating Activities -17.36M -15.39M -17.79M
Cash From Investing Activities -71.09M -219.7M 1.000K
Cash From Financing Activities 426.0K 173.2M 7.759M
Net Change In Cash -88.03M -61.95M -10.03M
YoY Change 1145.05% -143.9% -107.07%
FREE CASH FLOW
Cash From Operating Activities -$17.36M -$15.39M -$17.79M
Capital Expenditures -$8.000K -$3.000K -$1.000K
Free Cash Flow -$17.35M -$15.39M -$17.79M
YoY Change 130.45% 20.9% 41.76%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001816736
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P3Y6M
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39438
dei Entity Registrant Name
EntityRegistrantName
Disc Medicine, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1612845
dei Entity Address Address Line1
EntityAddressAddressLine1
321 Arsenal Street, Suite 101
dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
674-9274
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 Par Value
dei Trading Symbol
TradingSymbol
IRON
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
29725763
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
280663000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
360382000
CY2024Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
220282000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
0
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
7296000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5280000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
508241000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
365662000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
98000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
170000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1642000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1930000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
236000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
234000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
170000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1930000
CY2024Q2 us-gaap Assets
Assets
510217000
CY2023Q4 us-gaap Assets
Assets
367996000
CY2024Q2 us-gaap Assets
Assets
510217000
CY2023Q4 us-gaap Assets
Assets
367996000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4749000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
12629000
CY2024Q2 iron Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
10351000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4749000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
12629000
CY2024Q2 iron Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
10351000
CY2023Q4 iron Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
1986000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4451000
CY2023Q4 iron Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
1986000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4451000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6159000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
759000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
665000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6159000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
759000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
665000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
20310000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21439000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1078000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1436000
CY2023Q4 us-gaap Liabilities
Liabilities
22875000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
20310000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21439000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1078000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1436000
CY2024Q2 us-gaap Liabilities
Liabilities
21388000
CY2023Q4 us-gaap Liabilities
Liabilities
22875000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29707997
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24360233
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
3000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
730832000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29707997
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29707997
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24360233
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24360233
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
3000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
730832000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
533764000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
533764000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-60000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-241946000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-188645000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-60000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-241946000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-188645000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
488829000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
345121000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
488829000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
345121000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
510217000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
510217000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12100000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
47189000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32280000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7367000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5228000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15125000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10173000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
30852000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
17328000
us-gaap Operating Expenses
OperatingExpenses
62314000
us-gaap Operating Expenses
OperatingExpenses
42453000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-30852000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-17328000
us-gaap Operating Income Loss
OperatingIncomeLoss
-62314000
us-gaap Operating Income Loss
OperatingIncomeLoss
-42453000
CY2024Q2 us-gaap Interest Income Other
InterestIncomeOther
4573000
CY2023Q2 us-gaap Interest Income Other
InterestIncomeOther
2910000
us-gaap Interest Income Other
InterestIncomeOther
9092000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
367996000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23485000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12100000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
47189000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32280000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7367000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5228000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15125000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10173000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
30852000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
17328000
us-gaap Operating Expenses
OperatingExpenses
62314000
us-gaap Operating Expenses
OperatingExpenses
42453000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-30852000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-17328000
us-gaap Operating Income Loss
OperatingIncomeLoss
-62314000
us-gaap Operating Income Loss
OperatingIncomeLoss
-42453000
CY2024Q2 us-gaap Interest Income Other
InterestIncomeOther
4573000
us-gaap Interest Income Other
InterestIncomeOther
9092000
us-gaap Interest Income Other
InterestIncomeOther
5277000
CY2024Q2 iron Change In Fair Value Of Contingent Value Right Liability
ChangeInFairValueOfContingentValueRightLiability
0
CY2023Q2 iron Change In Fair Value Of Contingent Value Right Liability
ChangeInFairValueOfContingentValueRightLiability
-1500000
iron Change In Fair Value Of Contingent Value Right Liability
ChangeInFairValueOfContingentValueRightLiability
0
iron Change In Fair Value Of Contingent Value Right Liability
ChangeInFairValueOfContingentValueRightLiability
-1500000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-13000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-14000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4560000
us-gaap Interest Income Other
InterestIncomeOther
5277000
CY2024Q2 iron Change In Fair Value Of Contingent Value Right Liability
ChangeInFairValueOfContingentValueRightLiability
0
CY2023Q2 iron Change In Fair Value Of Contingent Value Right Liability
ChangeInFairValueOfContingentValueRightLiability
-1500000
iron Change In Fair Value Of Contingent Value Right Liability
ChangeInFairValueOfContingentValueRightLiability
0
iron Change In Fair Value Of Contingent Value Right Liability
ChangeInFairValueOfContingentValueRightLiability
-1500000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-13000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-14000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4560000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1405000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9078000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3772000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-26292000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15923000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-53236000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-38681000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
60000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
24000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
65000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
47000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-26352000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-15947000
us-gaap Net Income Loss
NetIncomeLoss
-53301000
us-gaap Net Income Loss
NetIncomeLoss
-38728000
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-26352000
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-26352000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-15947000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15947000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-53301000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-53301000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-38728000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-38728000
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25649043
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25649043
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21484955
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21484955
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25229456
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25229456
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20226923
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1405000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9078000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3772000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-26292000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15923000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-53236000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-38681000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
60000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
24000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-26352000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-15947000
us-gaap Net Income Loss
NetIncomeLoss
-53301000
us-gaap Net Income Loss
NetIncomeLoss
-38728000
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-26352000
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-26352000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-15947000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15947000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-53301000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-53301000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-38728000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-38728000
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25649043
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25649043
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21484955
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21484955
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25229456
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25229456
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20226923
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20226923
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.03
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.03
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.74
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.74
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.11
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.91
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.91
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-26352000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-15947000
us-gaap Net Income Loss
NetIncomeLoss
-53301000
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
6000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
6000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0
CY2024Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-66000
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-66000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-60000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-60000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20226923
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.03
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.91
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.91
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-26352000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-15947000
us-gaap Net Income Loss
NetIncomeLoss
-53301000
us-gaap Net Income Loss
NetIncomeLoss
-38728000
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
6000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
6000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0
CY2024Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-66000
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-66000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-60000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-60000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26412000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15947000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-53361000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-38728000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
345121000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
806000
CY2024Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
4058000
CY2024Q1 iron Common Stock In At The Market Offerings Net Of Issuance Costs
CommonStockInAtTheMarketOfferingsNetOfIssuanceCosts
518000
CY2024Q1 iron Stock Issued During Period Value Sale Of Common Stock In At The Market Offerings
StockIssuedDuringPeriodValueSaleOfCommonStockInAtTheMarketOfferings
14790000
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
245000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-26949000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
338071000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
567000
CY2024Q2 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
4091000
CY2024Q2 iron Common Stock In Registered Direct Offering Net Of Issuance Costs
CommonStockInRegisteredDirectOfferingNetOfIssuanceCosts
5472000
CY2024Q2 iron Stock Issued During Period Value Sale Of Common Stock In Registered Direct Offering
StockIssuedDuringPeriodValueSaleOfCommonStockInRegisteredDirectOffering
172512000
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
6000
CY2024Q2 iron Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriod
66000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-26352000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
488829000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
176600000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1067000
CY2023Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
1024000
CY2023Q1 iron Common Stock In Registered Direct Offering Net Of Issuance Costs
CommonStockInRegisteredDirectOfferingNetOfIssuanceCosts
80000
CY2023Q1 iron Stock Issued During Period Value Sale Of Common Stock In Registered Direct Offering
StockIssuedDuringPeriodValueSaleOfCommonStockInRegisteredDirectOffering
34148000
CY2023Q1 iron Pre Funded Warrants In Registered Direct Offering Net Of Issuance Costs
PreFundedWarrantsInRegisteredDirectOfferingNetOfIssuanceCosts
66000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26412000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15947000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-53361000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-38728000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
345121000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
806000
CY2024Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
4058000
CY2024Q1 iron Common Stock In At The Market Offerings Net Of Issuance Costs
CommonStockInAtTheMarketOfferingsNetOfIssuanceCosts
518000
CY2024Q1 iron Stock Issued During Period Value Sale Of Common Stock In At The Market Offerings
StockIssuedDuringPeriodValueSaleOfCommonStockInAtTheMarketOfferings
14790000
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
245000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-26949000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
338071000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
567000
CY2024Q2 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
4091000
CY2024Q2 iron Common Stock In Registered Direct Offering Net Of Issuance Costs
CommonStockInRegisteredDirectOfferingNetOfIssuanceCosts
5472000
CY2024Q2 iron Stock Issued During Period Value Sale Of Common Stock In Registered Direct Offering
StockIssuedDuringPeriodValueSaleOfCommonStockInRegisteredDirectOffering
172512000
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
6000
CY2024Q2 iron Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriod
66000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-26352000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
488829000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1067000
CY2023Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
1024000
CY2023Q1 iron Common Stock In Registered Direct Offering Net Of Issuance Costs
CommonStockInRegisteredDirectOfferingNetOfIssuanceCosts
80000
CY2023Q1 iron Stock Issued During Period Value Sale Of Common Stock In Registered Direct Offering
StockIssuedDuringPeriodValueSaleOfCommonStockInRegisteredDirectOffering
34148000
CY2023Q1 iron Pre Funded Warrants In Registered Direct Offering Net Of Issuance Costs
PreFundedWarrantsInRegisteredDirectOfferingNetOfIssuanceCosts
66000
CY2023Q1 iron Stock Issued During Period Value Sale Of Pre Funded Warrants In Registered Direct Offering
StockIssuedDuringPeriodValueSaleOfPreFundedWarrantsInRegisteredDirectOffering
28206000
CY2023Q1 iron Common Stock In At The Market Offerings Net Of Issuance Costs
CommonStockInAtTheMarketOfferingsNetOfIssuanceCosts
408000
CY2023Q1 iron Stock Issued During Period Value Sale Of Common Stock In At The Market Offerings
StockIssuedDuringPeriodValueSaleOfCommonStockInAtTheMarketOfferings
14591000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-22781000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
232855000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
242000
CY2023Q2 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
1309000
CY2023Q2 iron Common Stock In Follow On Public Offering Net Of Issuance Costs
CommonStockInFollowOnPublicOfferingNetOfIssuanceCosts
9272000
CY2023Q2 iron Stock Issued During Period Value Sale Of Common Stock In Follow On Public Offering
StockIssuedDuringPeriodValueSaleOfCommonStockInFollowOnPublicOffering
138508000
CY2023Q2 iron Stock Issued During Period Value Sale Of Pre Funded Warrants In Follow On Public Offering
StockIssuedDuringPeriodValueSaleOfPreFundedWarrantsInFollowOnPublicOffering
9373000
CY2023Q2 iron Common Stock In At The Market Offerings Net Of Issuance Costs
CommonStockInAtTheMarketOfferingsNetOfIssuanceCosts
119000
CY2023Q2 iron Stock Issued During Period Value Sale Of Common Stock In At The Market Offerings
StockIssuedDuringPeriodValueSaleOfCommonStockInAtTheMarketOfferings
4879000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-15947000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
371219000
us-gaap Profit Loss
ProfitLoss
-53301000
us-gaap Profit Loss
ProfitLoss
-38728000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
136000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
50000
us-gaap Share Based Compensation
ShareBasedCompensation
8149000
us-gaap Share Based Compensation
ShareBasedCompensation
2333000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0
CY2023Q1 iron Stock Issued During Period Value Sale Of Pre Funded Warrants In Registered Direct Offering
StockIssuedDuringPeriodValueSaleOfPreFundedWarrantsInRegisteredDirectOffering
28206000
CY2023Q1 iron Common Stock In At The Market Offerings Net Of Issuance Costs
CommonStockInAtTheMarketOfferingsNetOfIssuanceCosts
408000
CY2023Q1 iron Stock Issued During Period Value Sale Of Common Stock In At The Market Offerings
StockIssuedDuringPeriodValueSaleOfCommonStockInAtTheMarketOfferings
14591000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
232855000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
242000
CY2023Q2 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
1309000
CY2023Q2 iron Common Stock In Follow On Public Offering Net Of Issuance Costs
CommonStockInFollowOnPublicOfferingNetOfIssuanceCosts
9272000
CY2023Q2 iron Stock Issued During Period Value Sale Of Common Stock In Follow On Public Offering
StockIssuedDuringPeriodValueSaleOfCommonStockInFollowOnPublicOffering
138508000
CY2023Q2 iron Pre Funded Warrants In Follow On Public Offering Net Of Issuance Costs
PreFundedWarrantsInFollowOnPublicOfferingNetOfIssuanceCosts
627000
CY2023Q2 iron Stock Issued During Period Value Sale Of Pre Funded Warrants In Follow On Public Offering
StockIssuedDuringPeriodValueSaleOfPreFundedWarrantsInFollowOnPublicOffering
9373000
CY2023Q2 iron Common Stock In At The Market Offerings Net Of Issuance Costs
CommonStockInAtTheMarketOfferingsNetOfIssuanceCosts
119000
CY2023Q2 iron Stock Issued During Period Value Sale Of Common Stock In At The Market Offerings
StockIssuedDuringPeriodValueSaleOfCommonStockInAtTheMarketOfferings
4879000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-15947000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
371219000
us-gaap Profit Loss
ProfitLoss
-53301000
us-gaap Profit Loss
ProfitLoss
-38728000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
136000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
50000
us-gaap Share Based Compensation
ShareBasedCompensation
8149000
us-gaap Share Based Compensation
ShareBasedCompensation
2333000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
596000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0
iron Change In Fair Value Of Contingent Value Right Liability
ChangeInFairValueOfContingentValueRightLiability
0
iron Change In Fair Value Of Contingent Value Right Liability
ChangeInFairValueOfContingentValueRightLiability
-1500000
iron Noncash Lease Expense
NoncashLeaseExpense
288000
iron Noncash Lease Expense
NoncashLeaseExpense
134000
us-gaap Other Noncash Expense
OtherNoncashExpense
6000
us-gaap Other Noncash Expense
OtherNoncashExpense
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1616000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-128000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-8029000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-11476000
iron Increase Decrease In Accrued External Research And Development Expenses
IncreaseDecreaseInAccruedExternalResearchAndDevelopmentExpenses
8365000
iron Increase Decrease In Accrued External Research And Development Expenses
IncreaseDecreaseInAccruedExternalResearchAndDevelopmentExpenses
-200000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-2130000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-1791000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-264000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-140000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-48992000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-48190000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
64000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
41000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
219752000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-219816000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-41000
iron Proceeds From Sale Of Common Stock In Offerings Net Of Issuance Costs Paid
ProceedsFromSaleOfCommonStockInOfferingsNetOfIssuanceCostsPaid
172683000
iron Proceeds From Sale Of Common Stock In Offerings Net Of Issuance Costs Paid
ProceedsFromSaleOfCommonStockInOfferingsNetOfIssuanceCostsPaid
172755000
iron Change In Fair Value Of Contingent Value Right Liability
ChangeInFairValueOfContingentValueRightLiability
0
iron Change In Fair Value Of Contingent Value Right Liability
ChangeInFairValueOfContingentValueRightLiability
-1500000
iron Noncash Lease Expense
NoncashLeaseExpense
288000
iron Noncash Lease Expense
NoncashLeaseExpense
134000
us-gaap Other Noncash Expense
OtherNoncashExpense
6000
us-gaap Other Noncash Expense
OtherNoncashExpense
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1616000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-128000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-8029000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-11476000
iron Increase Decrease In Accrued External Research And Development Expenses
IncreaseDecreaseInAccruedExternalResearchAndDevelopmentExpenses
8365000
iron Increase Decrease In Accrued External Research And Development Expenses
IncreaseDecreaseInAccruedExternalResearchAndDevelopmentExpenses
-200000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-2130000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-1791000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-264000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-140000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-48992000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-48190000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
64000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
41000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
219752000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-219816000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-41000
iron Proceeds From Sale Of Common Stock In Offerings Net Of Issuance Costs Paid
ProceedsFromSaleOfCommonStockInOfferingsNetOfIssuanceCostsPaid
172683000
iron Proceeds From Sale Of Common Stock In Offerings Net Of Issuance Costs Paid
ProceedsFromSaleOfCommonStockInOfferingsNetOfIssuanceCostsPaid
172755000
iron Proceeds From Sale Of Pre Funded Warrants In Offerings Net Of Issuance Costs Paid
ProceedsFromSaleOfPreFundedWarrantsInOfferingsNetOfIssuanceCostsPaid
0
iron Proceeds From Sale Of Pre Funded Warrants In Offerings Net Of Issuance Costs Paid
ProceedsFromSaleOfPreFundedWarrantsInOfferingsNetOfIssuanceCostsPaid
37637000
us-gaap Proceeds From Sale Of Treasury Stock
ProceedsFromSaleOfTreasuryStock
14790000
us-gaap Proceeds From Sale Of Treasury Stock
ProceedsFromSaleOfTreasuryStock
19471000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1373000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1298000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
245000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
189091000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
231161000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-79717000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
182930000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
360616000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
194788000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
280899000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
377718000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
33000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1106000
iron Net Decrease In Right Of Use Assets Related To Lease Modifications And Reassessment Events
NetDecreaseInRightOfUseAssetsRelatedToLeaseModificationsAndReassessmentEvents
0
iron Net Decrease In Right Of Use Assets Related To Lease Modifications And Reassessment Events
NetDecreaseInRightOfUseAssetsRelatedToLeaseModificationsAndReassessmentEvents
237000
iron Proceeds From Sale Of Pre Funded Warrants In Offerings Net Of Issuance Costs Paid
ProceedsFromSaleOfPreFundedWarrantsInOfferingsNetOfIssuanceCostsPaid
0
iron Proceeds From Sale Of Pre Funded Warrants In Offerings Net Of Issuance Costs Paid
ProceedsFromSaleOfPreFundedWarrantsInOfferingsNetOfIssuanceCostsPaid
37637000
us-gaap Proceeds From Sale Of Treasury Stock
ProceedsFromSaleOfTreasuryStock
14790000
us-gaap Proceeds From Sale Of Treasury Stock
ProceedsFromSaleOfTreasuryStock
19471000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1373000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1298000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
245000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
189091000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
231161000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-79717000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
182930000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
360616000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
194788000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
280899000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
33000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1106000
iron Net Decrease In Right Of Use Assets Related To Lease Modifications And Reassessment Events
NetDecreaseInRightOfUseAssetsRelatedToLeaseModificationsAndReassessmentEvents
0
iron Net Decrease In Right Of Use Assets Related To Lease Modifications And Reassessment Events
NetDecreaseInRightOfUseAssetsRelatedToLeaseModificationsAndReassessmentEvents
237000
iron Net Decrease In Operating Lease Liabilities Due To Lease Modifications And Reassessment Events
NetDecreaseInOperatingLeaseLiabilitiesDueToLeaseModificationsAndReassessmentEvents
0
iron Net Decrease In Operating Lease Liabilities Due To Lease Modifications And Reassessment Events
NetDecreaseInOperatingLeaseLiabilitiesDueToLeaseModificationsAndReassessmentEvents
207000
iron Receivable Related To Deferred Issuance Costs On Sale Of Common Stock And Pre Funded Warrants In Offerings Included In Other Current Assets
ReceivableRelatedToDeferredIssuanceCostsOnSaleOfCommonStockAndPreFundedWarrantsInOfferingsIncludedInOtherCurrentAssets
0
iron Receivable Related To Deferred Issuance Costs On Sale Of Common Stock And Pre Funded Warrants In Offerings Included In Other Current Assets
ReceivableRelatedToDeferredIssuanceCostsOnSaleOfCommonStockAndPreFundedWarrantsInOfferingsIncludedInOtherCurrentAssets
400000
iron Deferred Issuance Costs On Sale Of Common Stock And Pre Funded Warrants In Offerings Included In Accounts Payable And Accrued Expenses1
DeferredIssuanceCostsOnSaleOfCommonStockAndPreFundedWarrantsInOfferingsIncludedInAccountsPayableAndAccruedExpenses1
171000
iron Deferred Issuance Costs On Sale Of Common Stock And Pre Funded Warrants In Offerings Included In Accounts Payable And Accrued Expenses1
DeferredIssuanceCostsOnSaleOfCommonStockAndPreFundedWarrantsInOfferingsIncludedInAccountsPayableAndAccruedExpenses1
558000
CY2024Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
500900000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-241900000
iron Net Decrease In Operating Lease Liabilities Due To Lease Modifications And Reassessment Events
NetDecreaseInOperatingLeaseLiabilitiesDueToLeaseModificationsAndReassessmentEvents
0
iron Net Decrease In Operating Lease Liabilities Due To Lease Modifications And Reassessment Events
NetDecreaseInOperatingLeaseLiabilitiesDueToLeaseModificationsAndReassessmentEvents
207000
iron Receivable Related To Deferred Issuance Costs On Sale Of Common Stock And Pre Funded Warrants In Offerings Included In Other Current Assets
ReceivableRelatedToDeferredIssuanceCostsOnSaleOfCommonStockAndPreFundedWarrantsInOfferingsIncludedInOtherCurrentAssets
0
iron Receivable Related To Deferred Issuance Costs On Sale Of Common Stock And Pre Funded Warrants In Offerings Included In Other Current Assets
ReceivableRelatedToDeferredIssuanceCostsOnSaleOfCommonStockAndPreFundedWarrantsInOfferingsIncludedInOtherCurrentAssets
400000
iron Deferred Issuance Costs On Sale Of Common Stock And Pre Funded Warrants In Offerings Included In Accounts Payable And Accrued Expenses1
DeferredIssuanceCostsOnSaleOfCommonStockAndPreFundedWarrantsInOfferingsIncludedInAccountsPayableAndAccruedExpenses1
171000
iron Deferred Issuance Costs On Sale Of Common Stock And Pre Funded Warrants In Offerings Included In Accounts Payable And Accrued Expenses1
DeferredIssuanceCostsOnSaleOfCommonStockAndPreFundedWarrantsInOfferingsIncludedInAccountsPayableAndAccruedExpenses1
558000
CY2024Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
500900000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-241900000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the Company’s condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to accrued research and development expenses; stock-based compensation expense; the fair value determinations for instruments accounted for at fair value; the fair value of the contingent value right (“CVR”) (see Note 3); the incremental borrowing rate for determining lease liabilities and right-of-use assets; and income taxes. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it has concluded to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">period in which they become known. Actual results may differ materially from those estimates or assumptions.</span>
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the Company’s condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to accrued research and development expenses; stock-based compensation expense; the fair value determinations for instruments accounted for at fair value; the fair value of the contingent value right (“CVR”) (see Note 3); the incremental borrowing rate for determining lease liabilities and right-of-use assets; and income taxes. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it has concluded to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">period in which they become known. Actual results may differ materially from those estimates or assumptions.</span>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">oncentration of Credit Risk and of Significant Suppliers </span><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits and limits its exposure to cash risk by placing its cash with high credit quality accredited financial institutions. The Company has concluded that it is not subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company relies, and expects to continue to rely, on a small number of vendors to manufacture supplies and to process its product candidates for its development programs. These programs could be adversely affected by a significant interruption in the manufacturing process or supply chain.</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">oncentration of Credit Risk and of Significant Suppliers </span><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits and limits its exposure to cash risk by placing its cash with high credit quality accredited financial institutions. The Company has concluded that it is not subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company relies, and expects to continue to rely, on a small number of vendors to manufacture supplies and to process its product candidates for its development programs. These programs could be adversely affected by a significant interruption in the manufacturing process or supply chain.</span></p>
CY2024Q2 iron Fair Value Of Transferred Assets From Level Two To Level One
FairValueOfTransferredAssetsFromLevelTwoToLevelOne
900000
iron Fair Value Of Transferred Assets From Level Two To Level One
FairValueOfTransferredAssetsFromLevelTwoToLevelOne
900000
CY2024Q2 iron Fair Value Of Transferred Assets From Level Two To Level One
FairValueOfTransferredAssetsFromLevelTwoToLevelOne
900000
iron Fair Value Of Transferred Assets From Level Two To Level One
FairValueOfTransferredAssetsFromLevelTwoToLevelOne
900000
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
220348000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
68000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
220282000
CY2023Q4 us-gaap Marketable Securities
MarketableSecurities
0
CY2024Q2 iron Aggregate Fair Value Of Marketable Securities In Unrealized Loss Position
AggregateFairValueOfMarketableSecuritiesInUnrealizedLossPosition
220300000
CY2023Q4 iron Aggregate Fair Value Of Marketable Securities In Unrealized Loss Position
AggregateFairValueOfMarketableSecuritiesInUnrealizedLossPosition
0
CY2024Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
26
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
0
CY2024Q2 us-gaap Debtor Reorganization Items Impairment Loss
DebtorReorganizationItemsImpairmentLoss
0
us-gaap Debtor Reorganization Items Impairment Loss
DebtorReorganizationItemsImpairmentLoss
0
CY2023Q2 us-gaap Debtor Reorganization Items Impairment Loss
DebtorReorganizationItemsImpairmentLoss
0
us-gaap Debtor Reorganization Items Impairment Loss
DebtorReorganizationItemsImpairmentLoss
0
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
220348000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
68000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
220282000
CY2023Q4 us-gaap Marketable Securities
MarketableSecurities
0
CY2024Q2 iron Aggregate Fair Value Of Marketable Securities In Unrealized Loss Position
AggregateFairValueOfMarketableSecuritiesInUnrealizedLossPosition
220300000
CY2023Q4 iron Aggregate Fair Value Of Marketable Securities In Unrealized Loss Position
AggregateFairValueOfMarketableSecuritiesInUnrealizedLossPosition
0
CY2024Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
26
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
0
CY2024Q2 us-gaap Debtor Reorganization Items Impairment Loss
DebtorReorganizationItemsImpairmentLoss
0
us-gaap Debtor Reorganization Items Impairment Loss
DebtorReorganizationItemsImpairmentLoss
0
CY2023Q2 us-gaap Debtor Reorganization Items Impairment Loss
DebtorReorganizationItemsImpairmentLoss
0
us-gaap Debtor Reorganization Items Impairment Loss
DebtorReorganizationItemsImpairmentLoss
0
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
280663000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
360382000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
236000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
234000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
280899000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
360616000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
280663000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
360382000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
236000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
234000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
280899000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
360616000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
381000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
245000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
98000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
170000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
381000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
245000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
170000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3493000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5790000
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
770000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
317000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
188000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
52000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4451000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6159000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3493000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5790000
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
770000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
317000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
188000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
52000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4451000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6159000
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 iron Common Stock Authorized And Reserved For Future Issuance
CommonStockAuthorizedAndReservedForFutureIssuance
2924576
CY2024Q2 iron Stock Reserved During Period Shares Exercise Of Prefunded Warrants
StockReservedDuringPeriodSharesExerciseOfPrefundedWarrants
204081
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4091000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1309000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8149000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2333000
CY2024Q2 iron Common Stock Authorized And Reserved For Future Issuance
CommonStockAuthorizedAndReservedForFutureIssuance
2924576
CY2024Q2 iron Stock Reserved During Period Shares Exercise Of Prefunded Warrants
StockReservedDuringPeriodSharesExerciseOfPrefundedWarrants
204081
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4091000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1309000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8149000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2333000
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
50586000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2459037
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.82
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M21D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
109078000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
696533
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
61.53
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
163579
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
8.46
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
55463
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
45.02
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
11952
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
113.93
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2924576
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
24.48
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y11M12D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
72721000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1451437
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
12.28
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y1M2D
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
48766000
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
50586000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2459037
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.82
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M21D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
109078000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
696533
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
61.53
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
163579
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
8.46
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
55463
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
45.02
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
11952
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
113.93
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2924576
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
24.48
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y11M12D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
72721000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1451437
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
12.28
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y1M2D
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
48766000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
7100000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2000000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0404
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0367
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y5M4D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y8M23D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.58
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.58
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
7100000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2000000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0404
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0367
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y5M4D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y8M23D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.58
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.58
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q2 us-gaap Share Price
SharePrice
61.53
CY2023Q2 us-gaap Share Price
SharePrice
35.36
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
5300000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2100000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1916
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
1916
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
0
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
0
CY2024Q2 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
CY2023Q2 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
100000
CY2024Q2 us-gaap Share Price
SharePrice
61.53
CY2023Q2 us-gaap Share Price
SharePrice
35.36
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
5300000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2100000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1916
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
1916
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
0
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
0
CY2024Q2 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
CY2023Q2 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
100000
us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
100000
CY2023Q3 iron Exercise Of Pre Funded Warrants Shares
ExerciseOfPreFundedWarrantsShares
1229224
iron Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
1229221
CY2024Q2 iron Pre Funded Warrants Outstanding
PreFundedWarrantsOutstanding
204081
us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
100000
CY2023Q3 iron Exercise Of Pre Funded Warrants Shares
ExerciseOfPreFundedWarrantsShares
1229224
iron Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
1229221
CY2024Q2 iron Pre Funded Warrants Outstanding
PreFundedWarrantsOutstanding
204081
CY2023Q2 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
9280
us-gaap Lessee Operating Lease Variable Lease Payment Terms And Conditions
LesseeOperatingLeaseVariableLeasePaymentTermsAndConditions
Variable lease payments include the Company’s allocated share of costs incurred for real estate taxes, utilities, and other operating expenses applicable to the leased premises.
CY2023Q2 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
9280
us-gaap Lessee Operating Lease Variable Lease Payment Terms And Conditions
LesseeOperatingLeaseVariableLeasePaymentTermsAndConditions
Variable lease payments include the Company’s allocated share of costs incurred for real estate taxes, utilities, and other operating expenses applicable to the leased premises.
CY2024Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
500000
CY2024Q2 iron Short Term Bank Loans And Notespayable Percentage
ShortTermBankLoansAndNotespayablePercentage
0.045
CY2024Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
500000
CY2024Q2 iron Short Term Bank Loans And Notespayable Percentage
ShortTermBankLoansAndNotespayablePercentage
0.045
CY2024Q2 iron Rule10 B51 Arr Modified Flag
Rule10B51ArrModifiedFlag
false
CY2024Q2 iron Non Rule10 B51 Arr Modified Flag
NonRule10B51ArrModifiedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 iron Rule10 B51 Arr Modified Flag
Rule10B51ArrModifiedFlag
false
CY2024Q2 iron Non Rule10 B51 Arr Modified Flag
NonRule10B51ArrModifiedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-093357-index-headers.html Edgar Link pending
0000950170-24-093357-index.html Edgar Link pending
0000950170-24-093357.txt Edgar Link pending
0000950170-24-093357-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
iron-20240630.htm Edgar Link pending
iron-20240630.xsd Edgar Link pending
iron-ex31_1.htm Edgar Link pending
iron-ex31_2.htm Edgar Link pending
iron-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
iron-20240630_htm.xml Edgar Link completed